彭耀进，中国科学院动物研究所，北京干细胞与再生医学研究院双聘“致一”研究员，科技伦理研究中心主任；兼任商务法务平台主任；生命科学学士、法律硕士、法学博士（Maastricht University, Netherlands）；主要研究领域包括生命科技法与伦理、知识产权与标准、科技与创新政策等；研究成果以第一作者或/和通讯作者在Nature Biotechnology, Nature Genetics, Cell Stem Cell, Protein & Cell, 《自然辩证法通讯》《国家安全研究》《中国科学院院刊》等国内外权威学术期刊发表论文40余篇。牵头起草制定中国首个干细胞研究伦理规范团体标准《人干细胞研究伦理审查技术规范》(T/CSCB 0009—2022)。主持国家级、省部级等项目多项，包括国家重点研发计划专项子课题、中国科学院A类战略性先导科技专项子课题、中国科协“科技治理”年度重点课题等；2021年入选“中国科学院青年创新促进会”，2021年荣获中国细胞生物学学会干细胞分会“干细胞社会公益先进个人”。

生物技术法律与伦理、知识产权与标准、科技政策与管理等

教学课程

生物医学法律与伦理（中国科学院大学，研究生课程）

1. Liang Yu, Ruohan Feng, Youhai Sun^*, Yaojin Peng*, Governance of cross-border genomic data sharing through a human-rights approach（跨境基因组数据共享的人权导向治理研究） (forthcoming)
2. Ruohan Feng, Yaojin Peng^*, Emerging Trends in Responsible Research: How China is Shaping Its Life and Health Data Governance Ecosystem （中国在生命与健康数据治理生态系统中的作用：负责任研究的新兴趋势） (forthcoming)
3. Yaojin Peng^*, Lulu Ding, Zhenyu Xiao, Moshi Song, Jianwei Lv, Guang-Hui Liu^*, Ethical Concerns in Aging Research: Perspectives of Global Frontline Researchers（衰老研究中的伦理关切：全球科技人员的视角）, SCIENCE CHINA Life Sciences, Jun 19, 2024 (IF 9.1, SCI)
4. Yaojin Peng^*, Aijin Ma, Zhenyu Xiao, et al. Technical specifications for ethics review of human stem cell research（人干细胞研究伦理审查技术规范）. Cell Proliferation. 2023;e13556. (IF 8.755, SCI)
5. Luxia Chen, Jianchao Gao, Ruohan Feng, Yaojin Peng^*, The Variability of Judicial Decisions in the Stem Cell Industry in China（中国干细胞领域司法判决的异质性）, Cell Stem Cell, 2023, 30(10):1294-1298. (IF 25.269, SCI)
6. Yaojin Peng^*, Lulu Ding, Moshi Song, Zhenyu Xiao, Jianwei Lv, Guang-Hui Liu^*, Acting on ethics and governance of aging research（衰老研究的伦理问题与治理框架）, Trends in Molecular Medicine, 2023, 29(6). (IF 15.272, SCI)
7. Yaojin Peng^*, Jianwei Lv, Lulu Ding, Xia Gong, Qi Zhou^*, Responsible Governance of Human Germline Genome Editing in China（中国人类生殖系基因组编辑的负责任治理）, Biology of Reproduction, 2022 May 27;ioac114. . (IF 4.285, SCI)
8. Lulu Ding, Zhenyu Xiao, Xia Gong, Yaojin Peng^*, Knowledge Graphs of Ethical Concerns of Cerebral Organoids（知识图谱解析脑类器官伦理蕴涵）, Cell Proliferation, 2022: e13239. (IF 8.755, SCI)
9. Yaojin Peng^*, Jianwei Lv, Zhenyu Xiao, Lulu Ding, Qi Zhou^*, A framework for the responsible reform of the 14-day rule in human embryo research（人类胚胎研究“14天规则”负责任变革的框架构建）, Protein & Cell, 2022, 13(8):552–558. (IF 14.870, SCI)
10. Zhenyu Xiao, Jianwei Lv, Siqi Zhao, Rosario Isasi, Xinwei Xie, Lei Dong, Yaojin Peng^*, The Potential Effects of the United States Abortion Ruling on Global Embryo/Foetal and Stem Cell Research（美国堕胎裁决对全球胚胎/胎儿与干细胞研究的潜在影响）, Life Medicine. 2022 Nov 18.
11. Jiani Cao, Jie Hao, Lei Wang, Yuanqing Tan, Yuchang Tian, Shiyu Li, Aijin Ma, Boqiang Fu, Jianwu Dai, Peijun Zhai, Peng Xiang, Yong Zhang, Tao Cheng^*, Yaojin Peng^*, Qi Zhou^*, Tongbiao Zhao^*. Developing standards to support the clinical translation of stem cells（干细胞临床转化的标准制定框架与策略）, STEM CELLS Transl Med. 2021; 10(S2): S85- S95. (IF: 7.655, SCI)
12. Yaojin Peng^*, Xiaoru Huang, Qi Zhou^*, Ethical and Policy Considerations for Human Embryo and Stem Cell Research in China（中国人类胚胎与干细胞研究的伦理与政策考量）, Cell Stem Cell, 2020, 27(4). (IF 25.269, SCI)
13. Jianwei Lv^#, Yeyang Su^#, Lingqiao Song, Xia Gong, Yaojin Peng^*, Stem cell ‘therapy’ advertisements in China: infodemic, regulations and recommendations（干细胞“治疗”虚假宣传乱象解析：信息失序、监管挑战与政策建议）, Cell Proliferation, 2020, 53(12). (IF 8.755, SCI)
14. Yaojin Peng^*, Patenting Human Embryonic Stem Cell Related Inventions in China: A Comparative Perspective（中国人类胚胎干细胞相关发明的专利保护研究：基于比较法视角）, PhD thesis (Faculty of Law, Maastricht University, Netherlands, September 2018)
15. Yaojin Peng^*, The Patentability of Human Embryonic Stem Cell Technology in China（中国人类胚胎干细胞技术的可专利性解析）, Nature Biotechnology, 2016, 34(1). DOI:10.1038/nbt.3417. (IF 43.113, SCI)
16. Yaojin Peng^*, The Morality and Ethics Governing CRISPR-Cas9 Patents in China（中国基因编辑专利的道德与伦理规制）, Nature Biotechnology, 2016, 34(6). DOI:10.1038/nbt.3590. (IF 43.113, SCI)
17. Yaojin Peng^*, Patent Term Extension in the Pharmaceutical Sector: An Asian Comparative Perspective（药品专利期限延长制度探析：基于亚洲比较法视角）, in The Future of Asian Trade Deals and IP (Kung-Chung Liu ed., Hart Publishing, forthcoming in 2019).
18. Yaojin Peng, UW-Google Intermediary Liability Research Project: Privacy Protection in China（UW-Google网络中介责任研究项目：中国隐私保护）, available at https://www.law.uw.edu/media/1404/china-intermediary-liability-of-isps-privacy.pdf.
19. Nguyen Xuan-Thao, Trademark apologetic justice: China’s trademark jurisprudence on reputational harm. in Foreign scholars on Chinese law series: intellectual property law (translated into Chinese by Yaojin Peng^*), in Intellectual Property Law of China, Encyclopedia of China Publishing House, 2018).
20. Qianwen Chen, Siqi Zhao, Yaojin Peng, Organoids: technological innovation and ethical controversies（类器官：技术创新与伦理争议）, Synthetic Biology Journal《合成生物学》,2024, 5. DOI: 10.12211/2096-8280.2024-009.
21. ShuaiShuai Niu , Lei1 Wang, TongBiao Zhao, Yaojin Peng^*, Jie Hao^*, Challenges and opportunities in the development of standardized stem cell resource centers（干细胞资源库的标准化建设：挑战和机遇）Sci Sin Vitae《中国科学：生命科学》, 2024, 54, doi: 10.1360/SSV-2024-0118. （CSCD，北大核心）
22. Jianchao Gao, Yaojin Peng, Wei Wei, Shuang Lu, Chenyan Gao, Panorama of human embryo-derived cells in biomedicine and progress in their research and regulation（人胚胎来源细胞在生物医药领域的应用历史及研究和监管进展）Bulletin of Chinese Academy of Sciences《中国科学院院刊》, 2024,39(2):388-396. （CSCD，中文核心）
23. Lulu Ding, Siqi Zhao, Yaojin Peng^*, Tension between Technology and Ethics of Human-animal Chimera Research（人-动物嵌合体研究的技术-伦理张力）Studies in Science of Science 《科学学研究》, 2023.https://doi.org/10.16192/j.cnki.1003-2053.20230915.001. （CSSCI，北大核心）
24. Luxia Chen, Xinwei Xie, Zhenyu Xiao, Yaojin Peng^*, Challenges of mitochondrial replacement technology and its regulation（线粒体置换技术的挑战及其规制），Biomedical Transformation《生物医学转化》, 2022,3(04):96-105. （CSCD）
25. Jianwei Lv，Yaojin Peng^*，Reconstruction on the Withdrawal of Informed Consent System for Human Biological Samples（人体生物样本知情同意退出制度重塑），Science and Society《科学与社会》，2022,12(2):137-156.（CSSCI扩展板）
26. Yaojin Peng^*，Jianwei Lv，The challenges and solutions of the 14-day rule in human embryo research（人类胚胎研究“14天规则”的挑战与出路）, Journal of Dialectics of Nature《自然辩证法通讯》, 2022,44(10):77-86 (CSSCI，北大核心)（被评委《自然辩证法通讯》2022年度最受欢迎的10篇论文）
27. Yaojin Peng, Qi Zhou^*，China’s Strategies for Governance of Biotechnological Changes and New Ethical Challenges（应对生物技术变革与伦理新挑战的中国方略）, Bulletin of Chinese Academy of Sciences《中国科学院院刊》, 2021,36(11):1288-1297. （CSCD，中文核心）
28. Yaojin Peng^*, The Era of Synthetic Biology: Biosafety, Biosecurity and Governance（合成生物学时代：生物安全、生物安保与治理），Journal of International Security Studies《国际安全研究》，2020, 38(5): 29-57.（CSSCI）
29. Yaojin Peng^*, Li Wei, Ethical issues and the governance of life science and technology: A case study on human-animal chimeras（生命科技伦理问题与治理策略——以人-动物嵌合体研究为例）, Science & Technology Review（科技导报），2020, 38(5): 42-49.（CSCD，中文核心）
30. Qi Zhou^*, Yaojin Peng, The Era of Biotechnology and Biosafety（这是生物技术的时代，也是生物安全的时代）, Journal of Engineering Studies（工程研究——跨学科视野中的工程），2020, 12(1).（CSCD，中文核心）
31. Yaojin Peng^*，Designer baby: How to face it（“设计婴儿”：我们将怎样面对）, Frontier Science（前沿科学）, 2019(3): 93-96.
32. Yaojin Peng^*, Intellectual Property Protection Concerning Stem Cell Research in China: Predicament and Solutions（中国干细胞知识产权保护的困境与对策）, Chinese Bulletin of Life Science（生命科学）, 2016, 28(8).（CSCD、北大核心）
33. Yaojin Peng^*, Employees’ Invention Compensation Regime in the Netherlands and Its Enlightenment to China（荷兰职务发明奖酬制度及其借鉴意义）, Journal of Fujian Jiangxia University（福建夏学院学报）, 2017, 7(4): 29-38.
34. Yong Wan, Jie Wang, Tianxiang He, Yaojin Peng, Zijiao Cheng, The Protection of Privacy in China（中国的隐私保护）, Journal of Shantou University （汕头大学学报）, 2017, 33(11) .

参与的标准

1. Yu M, Lei W, Cao J, Wang L, Ma A, Zhao ZA, Yang HT, Shen Z, Lan F, Cao F, Liang P, Pei X, Xiang AP, Yu J, Zhang Y, Zhang Y, Li Q, Zhou J, Wei J, Peng Y, Zhu H, Liang L, Cao N, Fu B, Hao J, Zhao T, Hu S. Requirements for human cardiomyocytes（人类心肌细胞的规范要求）. Cell Prolif. 2022 Apr;55(4):e13150. doi: 10.1111/cpr.13150.
2. Chen X, Huang J, Wu J, Hao J, Fu B, Wang Y, Zhou B, Na T, Wei J, Zhang Y, Li Q, Hu S, Zhou J, Yu J, Wu Z, Zhu H, Cao J, Wang L, Peng Y, Liang L, Ma A, Zhang Y, Zhao T, Xiang AP. Human mesenchymal stem cells. Cell Prolif. 2022 Apr;55(4):e13141. doi: 10.1111/cpr.13141.
3. Peng Z, Wu J, Hu S, Ma A, Wang L, Cao N, Zhang Y, Li Q, Yu J, Meng S, Na T, Shi X, Li M, Liu H, Qian L, Tian E, Lin F, Cao J, Peng Y, Zhu H, Liang L, Hao J, Zhao T, Cheng X, Pan G. Requirments for primary human hepatocyte. Cell Prolif. 2022 Apr;55(4):e13147. doi: 10.1111/cpr.13147.
4. Wang L, Cao J, Peng Y, Fu B, Jin Z, Hu Y, Wu W, Xiang AP, Hu S, Yu J, Zhang Y, Wei J, Zhang Y, Li Q, Zhou J, Zhai P, Zhu H, Liang L, Ma A, Stacey G, Zhao T, Hao J. Human retinal pigment epithelial cells. Cell Prolif. 2022 Apr;55(4):e13153. doi: 10.1111/cpr.13153.
5. Nan X, Zhang B, Hao J, Yue W, Fu B, Qu M, Zhang Y, Wang H, Fang F, Wei J, Li Q, Hu S, Yu J, Gao Y, Liu Q, Cao J, Wang L, Peng Y, Zhu H, Liang L, Ma A, Zhou J, Zhao T, Pei X. Requirements for human haematopoietic stem/progenitor cells. Cell Prolif. 2022 Apr;55(4):e13152. doi: 10.1111/cpr.13152.
6. Zhang Y, Wei J, Cao J, Zhang K, Peng Y, Deng H, Kang J, Pan G, Zhang Y, Fu B, Hu S, Na J, Liu Y, Wang L, Liang L, Zhu H, Zhang Y, Jin ZB, Hao J, Ma A, Zhao T, Yu J. Requirements for human-induced pluripotent stem cells. Cell Prolif. 2022 Apr;55(4):e13182. doi: 10.1111/cpr.13182.